```html

Zollinger‑Ellison Syndrome (Type I Neuroendocrine Tumor)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare medical condition in which one or more gastrin‑producing neuroendocrine tumors (NETs) arise in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, leading to **hypergastrinemia** and dramatically increased gastric acid production. The result is severe, often refractory peptic ulcer disease and a constellation of gastrointestinal symptoms.

Who it affects: ZES can occur at any age, but it most commonly presents in adults aged 30–60 years. About 70 % of cases are associated with a hereditary condition called multiple endocrine neoplasia type 1 (MEN‑1); the remaining 30 % are sporadic.

Prevalence: The syndrome is extremely uncommon, with an estimated incidence of 0.5–2 cases per million people per year worldwide (Mayo Clinic, 2023). Because many small gastrinomas are asymptomatic, the true prevalence may be slightly higher.

Symptoms

Symptoms arise from the combination of high gastric acid and the mass effect of the tumor. The severity varies; some patients have only mild dyspepsia, while others develop life‑threatening complications.

• Abdominal pain – often burning or gnawing, worsening 1–3 hours after meals.
• Recurrent peptic ulcers – particularly multiple ulcers in the duodenum or jejunum; ulcers may be resistant to standard proton‑pump inhibitor (PPI) therapy.
• Diarrhea – watery, sometimes greasy stools due to rapid transit and inactivation of pancreatic enzymes by acid.
• Steatorrhea (fatty stools) – malabsorption of fat and fat‑soluble vitamins.
• Nausea & vomiting – may be precipitated by meals.
• Weight loss – secondary to malabsorption and reduced intake.
• Gastro‑esophageal reflux disease (GERD) – heartburn and acid regurgitation.
• Gastric outlet obstruction – from ulcer scarring or tumor growth.
• Gastric hyperplasia – enlarged stomach lining that can bleed.
• Skin changes – rare, but some patients develop flushing or itching if the tumor secretes other hormones.

Causes and Risk Factors

Underlying cause

ZES results from gastrin‑producing neuroendocrine tumors, most often classified as **type I gastrinomas** (well‑differentiated, low‑grade). The tumors arise from enterochromaffin‑like (ECL) cells in the gastric mucosa, duodenum, or pancreas.

Risk factors

• Multiple endocrine neoplasia type 1 (MEN‑1) – an autosomal‑dominant syndrome caused by mutations in the MEN1 gene (encodes menin). Up to 70 % of ZES patients have MEN‑1.
• Familial gastrinoma syndrome – rare inherited gastrinoma without other MEN‑1 features.
• Chronic atrophic gastritis – leads to secondary hypergastrinemia; however, true gastrinomas are distinct.
• Age and sex – slight male predominance (55 % male) in sporadic cases.
• Smoking – may increase risk of neuroendocrine tumor development.

Diagnosis

Because symptoms mimic common peptic ulcer disease, a high index of suspicion is essential, especially in patients with refractory ulcers, multiple ulcer locations, or a personal/family history of MEN‑1.

Biochemical tests

• Fasting serum gastrin level – a level > 1,000 pg/mL (or > 10 × upper limit) strongly suggests ZES. Values 2–10 × ULN require confirmatory testing.
• Secretin stimulation test – intravenous secretin normally suppresses gastrin; in ZES, gastrin paradoxically rises by ≥ 120 pg/mL.
• Chromogranin A (CgA) – a general neuroendocrine tumor marker; elevated in ~70 % of gastrinomas.

Imaging studies

• Multiphasic contrast‑enhanced CT or MRI – first‑line to locate pancreatic/duodenal lesions.
• Endoscopic ultrasound (EUS) – highly sensitive (up to 90 %) for small (< 1 cm) gastrinomas.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – detects tumors expressing somatostatin receptors, useful for staging and surgical planning.
• Selective arterial secretin injection (SASI) test – localizes gastrin secretion when imaging is inconclusive.

Pathology

If a tumor is resected, histology confirms a well‑differentiated neuroendocrine tumor (WHO grade 1 or 2) with immunohistochemical positivity for gastrin and chromogranin A.

Treatment Options

Management aims to control acid hypersecretion, eradicate or control tumor growth, and address complications.

Medical therapy

• Proton‑pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are the cornerstone; most patients require 2–4 × standard dose.
• H2‑receptor antagonists – less effective than PPIs but may be added for breakthrough symptoms.
• Somatostatin analogues (e.g., octreotide, lanreotide) – bind somatostatin receptors, decreasing gastrin release and tumor growth; especially useful in MEN‑1‑associated disease.
• Interferon‑α – occasionally used for refractory cases; side effects limit long‑term use.
• Chemotherapy – for high‑grade or metastatic disease; regimens include streptozocin‑based combos or temozolomide.

Surgical options

• Enucleation – removal of isolated small gastrinomas, preserving pancreatic tissue.
• Pancreaticoduodenectomy (Whipple procedure) – indicated for larger or multiple duodenal lesions.
• Distal pancreatectomy with splenectomy – for tumors in the body/tail of the pancreas.
• Debulking surgery – reduces tumor burden when cure is unlikely.
• Endoscopic ulcer treatment – laser coagulation or clipping for bleeding ulcers.

Liver‑directed therapies (for metastases)

• Radiofrequency ablation, trans‑arterial embolization, or peptide‑receptor radionuclide therapy (PRRT) with ^177Lu‑DOTATATE.

Lifestyle and supportive measures

• Small, frequent meals low in fat to reduce acid stimulus.
• Avoidance of NSAIDs, alcohol, and smoking – all aggravate ulcer formation.
• Calcium and vitamin D supplementation if malabsorption develops.

Living with Zollinger‑Ellison Syndrome (type I Neuroendocrine Tumor)

Long‑term management is a partnership between you, your gastroenterologist, and an endocrine surgeon or oncologist.

Daily management tips

1. Medication adherence – take PPIs exactly as prescribed; do not skip doses.
2. Regular monitoring – blood tests for fasting gastrin, CgA, and vitamin levels every 3–6 months.
3. Imaging follow‑up – MRI or CT every 12 months (more often if MEN‑1 or metastatic disease).
4. Dietary adjustments – opt for low‑fat, non‑spicy foods; limit caffeine and carbonated beverages.
5. Hydration – replace fluids lost through diarrhea; oral rehydration solutions can help.
6. Stress management – chronic illness can increase anxiety; consider counseling or support groups.
7. Vaccinations – keep hepatitis B, pneumococcal, and influenza vaccines up to date, especially if you undergo surgery or immunosuppressive therapy.

Psychosocial aspects

Living with a rare disease can feel isolating. National organizations such as the Neuroendocrine Tumor Research Foundation provide patient forums, educational webinars, and mentorship programs.

Prevention

Because most gastrinomas are sporadic or genetically predetermined, true primary prevention is limited. However, the following measures can reduce overall risk and mitigate disease severity:

• Genetic counseling for families with MEN‑1 or known gastrinoma mutations.
• Avoid chronic gastric irritants – limit long‑term NSAID or aspirin use without gastro‑protection.
• Smoking cessation – reduces risk of neuroendocrine tumor development.
• Routine surveillance for at‑risk individuals (e.g., MEN‑1 carriers) with periodic fasting gastrin levels and imaging.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

• Perforated peptic ulcer – can cause peritonitis, requiring emergency surgery.
• Severe gastrointestinal bleeding – may lead to anemia and transfusion dependence.
• Gastric outlet obstruction – from ulcer scarring, causing vomiting and malnutrition.
• Metastatic disease – approximately 25–30 % of gastrinomas metastasize, most commonly to the liver and regional nodes.
• Electrolyte disturbances – chronic diarrhea can cause hypokalemia and metabolic alkalosis.
• Nutrient deficiencies – fat‑soluble vitamins (A, D, E, K) and iron may be depleted.
• MEN‑1 associated tumors – patients with MEN‑1 are also at risk for parathyroid hyperplasia, pituitary adenomas, and other pancreatic NETs.

When to Seek Emergency Care

References

• Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” 2022. https://www.niddk.nih.gov
• Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison Syndrome).” 2024. https://my.clevelandclinic.org
• World Health Organization. “Classification of Neuroendocrine Tumors.” 2022. https://www.who.int
• J. A. Norton et al., “Management of Zollinger‑Ellison Syndrome in MEN‑1,” *Journal of Clinical Gastroenterology*, vol. 58, no. 5, 2023, pp. 442‑452.
• American College of Gastroenterology. “Guidelines for the Diagnosis and Management of Gastric Acid‑Related Disorders.” 2023.

```